


Testing Taskforce: New California COVID-19 deaths

7 day Average Deaths




Average test positivity past 7 days 5.5%, up 0.2% from last week
7 day average deaths remain at low levels.

Wastewater data


Show nationwide average

Total results Last 6 months Last 6 weeks

Wastewater: Effective SARS-CoV-2 virus concentration (copies / mL of sewage)




Source: Wastewater data from Biobot Analytics



<https://biobot.io/data/>

Daily new confirmed COVID-19 cases per million people

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.



COVID-19 cases are low in many countries around the world. In the US cases, hospitalizations and deaths are staying steady and relatively low.


CDC NOWCAST – Variant Proportions in the US

This excludes traveler sequences from airport monitoring

Weighted and Nowcast Estimates in United States for 2-Week Periods in 3/5/2023 – 6/24/2023

Nowcast Estimates in United States for 6/11/2023 – 6/24/2023

Hover over (or tap in mobile) any lineage of interest to see the amount of uncertainty in that lineage's estimate.



		USA			
WHO label	Lineage #	%Total	95%PI		
Omicron	XBB.1.5	27.0%	23.8-30.5%	-13.3%	
	XBB.1.16	19.9%	17.1-23.0%	+4.5%	
	XBB.1.9.2	13.0%	7.9-20.4%	+4.2%	
	XBB.1.9.1	11.4%	10.0-13.0%	+0.1%	
	XBB.2.3	10.6%	7.7-14.4%	+2.7%	
	XBB.1.16.1	9.5%	7.7-11.8%	+2.6%	
	EU.1.1	1.7%	1.0-2.7%	+0.4%	
	FE.1.1	1.6%	0.8-2.8%	+0.3%	
	XBB.1.5.68	1.4%	0.8-2.3%	+0.1%	
	XBB.1.5.1	1.2%	0.8-1.6%	-0.4%	
	XBB.1.5.10	1.2%	0.7-1.9%	-0.1%	
	XBB	0.9%	0.6-1.4%	-0.5%	
	FD.2	0.4%	0.1-1.0%	-0.2%	
	CH.1.1	0.2%	0.1-0.2%	-0.1%	
	BA.2.12.1	0.1%	0.0-0.4%		
	BQ.1.1	0.0%	0.0-0.1%		
BA.2	0.0%	0.0-0.0%			
BQ.1	0.0%	0.0-0.0%			
BN.1	0.0%	0.0-0.0%			
BA.2.75	0.0%	0.0-0.0%			
BA.5	0.0%	0.0-0.0%			
BF.7	0.0%	0.0-0.0%			
Other	Other*	0.0%	0.0-0.1%		

3 new sublineages broken out into their own categories:

XBB.1.5.68

EU.1.1
(XBB.1.5.26.1.1)

FE.1.1 (XBB.1.18.1.1.1)

Pango lineage alias key:

https://github.com/cov-lineages/pango-designation/blob/master/pango_designation/alias_key.json

Emerging sub-lineages COVID-19

- XBB.1.5.68 – Most prevalent in the USA. 28% relative growth advantage over XBB.1.5 but negative growth compared to XBB.1.16
- EU.1.1 (XBB.1.5.26.1.1)- Most prevalent in the USA, Germany and Austria. 41% relative growth advantage over XBB.1.5 and 3% growth advantage compared to XBB.1.16
- FE.1.1 (XBB.1.18.1.1.1)- Most prevalent in the USA, China and Brazil. 53% relative growth advantage over XBB.1.5 and 12% growth advantage compared to XBB.1.16

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid
- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date




Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date





Figure 19. Percentage of Other Respiratory Pathogen Detections at Clinical Sentinel Laboratories, 2022-2023 Season to Date



How to access free COVID-19 tests

	COVID-19 Vaccines	COVID-19 Treatment	COVID-19 Testing
Medi-Cal Fee-for-Service	Continues: Free COVID-19 vaccines. ¹	Continues for now: Free COVID-19 treatment and related doctor visits is guaranteed at least until September 30, 2024. ²	Continues: Free COVID-19 testing if ordered by a doctor. Continues for now: Eight free at-home test kits per month are guaranteed at least until September 30, 2024. ²
Medi-Cal Managed Care	Continues: Free COVID-19 vaccines. ³	Continues: Free COVID-19 treatment and related doctor appointments. ³	Continues: Free COVID-19 testing, including eight free at-home test kits per month. ³
Medicare	Continues: Free COVID-19 vaccines with in-network providers. ⁴	Continues for now: Free COVID-19 oral medications. Continues: COVID-19 hospital visits and doctor appointments with in-network providers are covered, but cost-sharing varies by plan. ⁴	Continues: Free COVID-19 testing if ordered by a doctor. The cost of at-home test kits for people with Medicare Advantage will vary by plan and might be free in some plans. Ends May 11, 2023: Free COVID-19 at-home tests. Some Medicare Advantage plans might still provide free at-home tests. ⁴
Private Plans Regulated by California	Continues: Free COVID-19 vaccines with in-network providers. Ends November 11, 2023: Free COVID-19 vaccines with out-of-network providers.	Continues: Free COVID-19 treatment and related doctor appointments with in-network providers. Ends November 11, 2023: Free COVID-19 treatment and related doctor visits with out-of-network providers. ³	Continues: Free COVID-19 testing with in-network providers, including 8 at-home test kits per month. Ends November 11, 2023: Free COVID-19 testing with out-of-network providers. ³
Uninsured	Continues for Now: Low-cost or free COVID-19 health care provider visits at FQHCs and free clinics. Free COVID-19 vaccines and oral medications at most pharmacies, community organizations, clinics and FQHCs. ⁵ Expires May 31, 2023: Free COVID-19 testing, and IV medications related to health care provider visits through the Department of Health Care Service's COVID-19 Uninsured Program. ⁵		

- <https://testinglocator.cdc.gov/> - For people without insurance
- <https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/COVID-19/Simple-COVID-19-Coverage-Change.pdf>

SARS-CoV-2, Influenza Virus and RSV Result Reporting

- Report results electronically to the CalREDIE system within 24 hrs
- Facilities certified under CLIA to perform non-waived testing must report:
 - All laboratory-based SARS-CoV-2 and influenza virus Nucleic Acid Amplification Tests (NAAT) results, including positive and non-positive (negative, indeterminate, etc.) and are requested to report all RSV NAAT results, including positive and non-positive (negative, indeterminate, etc.)
 - All SARS-CoV-2 and influenza virus non-NAAT diagnostic testing (e.g., high throughput antigen testing) results, including positive and non-positive results of and are requested to report RSV non-NAAT diagnostic testing results, including positive and non-positive (negative, indeterminate, etc.)
- Facilities conducting testing with a CLIA Certificate of Waiver (e.g., skilled nursing facilities, schools):
 - Reporting of positive and non-positive results for SARS-CoV-2, influenza virus, and RSV is **not** required

Thank you for reporting results for these important pathogens. Please reach out to calrediehelp@cdph.ca.gov with any questions.

Testing Taskforce is Shutting Down June 30

- For now, we recommend that antigen tests can be accessed for free via the methods in the slide above.
- An announcement regarding the potential availability for a limited supply of antigen tests for the winter respiratory season will happen later in the summer
- Reach out to the CDPH HAI team for further information or questions on testing